Disruption of active trans-sialidase genes impairs the egress from mammalian host cells and generates highly attenuated Trypanosoma cruzi parasites

Caldas, Gabriela de Assis Burle; Santos, Nailma S. A. dos; Castro, Júlia T. de; Silva, Viviane Grazielle; Pereira, Milton C. A.; Gazzinelli, Ricardo Tostes; Schenkman, Sergio; Teixeira, Santuza Maria Ribeiro.
No convencional en Inglés | ARCA | ID: arc-46702

Documentos relacionados

  1. Why do we still have not a vaccine against Chagas disease?
  2. <i>Trypanosoma cruzi trans</i>-Sialidase as a Potential Vaccine Target Against Chagas Disease.
  3. Preclinical advances and the immunophysiology of a new therapeutic Chagas disease vaccine.
  4. Assessment of a combined treatment with a therapeutic vaccine and benznidazole for the Trypanosoma cruzi chronic infection.
  5. Preventive Pharmacovigilance: timely and precise prevention of adverse events through person-level patient screening and dose-level product surveillance.
  6. Spending the Best but Banking the Rest.
  7. Self-Assembling Nanoparticles Usher in a New Era of Vaccine Design.
  8. Trained Immunity: Reprogramming Innate Immunity in Health and Disease.
  9. Macrophage-infectivity potentiator of <i>Trypanosoma cruzi</i> (TcMIP) is a new pro-type 1 immuno-stimulating protein for neonatal human cells and vaccines in mice.
  10. Vaccine hesitancy: current and future challenges.